Strategies for Slowing Progression of Diabetic Nephropathy

  • Anne Marie V. Miles
  • Eli A. Friedman

Abstract

Over the past 15 years renal disease attributed to diabetes mellitus has emerged as the leading cause of end-stage renal disease (ESRD) in the United States (Figure 1) (1). ESRD is also the leading cause of death in patients with insulin-dependent diabetes mellitus (IDDM) (2); ESRD registries and death certificates, however, may incorrectly presume that all “insulin-treated” diabetics have IDDM, hence deaths in patients with noninsulin dependent diabetes (NIDDM) may also contribute to this statistic. Indeed, most diabetics in ESRD programs have NIDDM, because of the much higher prevalence of NIDDM over IDDM (1). The health care costs per year incurred by diabetics with ESRD in the United States are 20% greater than non-diabetic ESRD patients (3), and the overall expense of medical care for diabetic ESRD patients exceeds $1 billion per year (4). Data from around the world confirm the dominant importance of diabetes to ESRD programs: The European Dialysis and Transplant Association (EDTA) reports that, in 1972, 0.5% of patients treated for ESRD were diabetics, while, in 1985, the figure had risen to 10.5% (5). In Australia and New Zealand, the annual increase in new diabetic ESRD patients has been less marked: 8% in 1985 versus 14% in 1990 (6); while in Japan, in 1990, diabetes accounted for 26.2% of 16,543 new patients begun on maintenance hemodialysis (7).

Keywords

Albumin Neuropathy Angiotensin Indomethacin Nifedipine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    United States Renal Data System: USRDS 1991 Annual Data Report The National Institutes of Health, National Institute of Diabetes and Digestive Diseases. Bethesda, MD, August 1991.Google Scholar
  2. 2.
    Borch-Johnsen K: Incidence of nephropathy in insulin dependent diabetes as related to mortality. In: “The kidney and hypertension in diabetes mellitus” (Ed CE Mogensen), Topics in Renal Medicine (Series Ed VE Andreucci), Martinus Nijhoff, Boston, pp 33–40.Google Scholar
  3. 3.
    Smith DG, Harlan LC, Hawthorne VM: The charges for ESRD treatments of diabetics. J Clin Epidemiol, 42: 111–118, 1989.PubMedCrossRefGoogle Scholar
  4. 4.
    Eggers PW: Effect of transplantation on the Medicare end-stage renal disease program. N Engl J Med, 318: 223–229, 1988.PubMedCrossRefGoogle Scholar
  5. 5.
    Brunner FP: End stage renal disease due to diabetic nephropathy: data from the EDTA Registry. J Diab Compi, 3: 127–135, 1989. ANZDATA Report 1991. Australia and New Zealand Dialysis and Transplant Registry. Editor: Disney APS. Adelaide, South Australia.Google Scholar
  6. 6.
    Balodimus MC: Diabetic nephropathy. In: “Joslin’s Diabetes” (Eds A Marble, P White, RF Bradley, LP Krall), Lea & Febiger, Philadelphia, 1971, pp 526–561.Google Scholar
  7. 7.
    Agishi T: Annual Statistical Report, 1991. Japanese Society for Dialysis Therapy.Google Scholar
  8. 8.
    Mogensen CE, Christensen CK, Vittinghus E: The stages in diabetic renal disease with emphasis on the stage of incipient diabetic nephropathy. Diabetes, 32(Suppl 2): 64–78, 1983.PubMedGoogle Scholar
  9. 9.
    Cambier P: Application de la theorie de Rehberg a l’etude clinique des affections rénales et du diabetes. Ann Med, 35: 273–299, 1934.Google Scholar
  10. 10.
    Spuhler O: Zur Physio Pathologie der Niere. Hans Huber, Bern, 1946, pp 45.Google Scholar
  11. 11.
    Fiaschi E, Grassi B, Andres G: La funzione renale nel diabete mellito. Rassegna di fisiopatologia clinica e terapeutica, 24: 372, 1952.Google Scholar
  12. 12.
    Stalder G, Schmid R: Severe functional disorders of glomerular capillaries and renal hemodynamics in treated diabetes mellitus in childhood. Ann Pediatr, 193: 129–138, 1959.Google Scholar
  13. 13.
    Ditzel J, Schwartz M: Abnormally increased glomerular filtration rate in short-term insulin-treated diabetic subjects. Diabetes, 16: 264–267, 1967.PubMedGoogle Scholar
  14. 14.
    Mogensen CE: Kidney function and glomerular permeability to macromolecules in early juvenile diabetes. Scand J Clin Lab Invest, 28: 79–90, 1971.PubMedCrossRefGoogle Scholar
  15. 15.
    Mogensen CE: Glomerular filtration rate and renal plasma flow in short term and long term juvenile diabetes. Scand J Clin Lab Invest, 28: 91–100, 1971.PubMedCrossRefGoogle Scholar
  16. 16.
    Ditzel J, Junker K: Abnormal glomerular filtration rate, renal plasma flow, and renal protein excretion in recent and short term diabetics. Br Med J, 2: 13–19, 1972.PubMedCrossRefGoogle Scholar
  17. 17.
    Mogensen CE: Kidney function and glomerular permeability to macromolecules in juvenile diabetes. Dan Med Bull, 19(Suppl 3): 24, 1972.Google Scholar
  18. 18.
    Hannedouche TP, Delgado AG, Gnionsahe DA, Boitard C, Lacour B, Grunfeld JP: Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes. Kidney Int, 37: 1126–1133, 1990.PubMedCrossRefGoogle Scholar
  19. 19.
    Wiseman MJ, Viberti GC, Keen H: Threshold effect of plasma glucose in the glomerular hyperfiltration of diabetes. Nephron, 38: 257–260, 1984.PubMedCrossRefGoogle Scholar
  20. 20.
    Mogensen CE, Christensen CK: Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med, 311: 89–93, 1984.PubMedCrossRefGoogle Scholar
  21. 21.
    Christiansen JS: On the pathogenesis of the increased glomerular filtration rate in short-term insulin-dependent diabetes. Dan Med Bull, 31: 349–361, 1984.PubMedGoogle Scholar
  22. 22.
    Castellino P, Shohat J, DeFronzo RA: Hyperfiltration and diabetic nephropathy: Is it the beginning? Or is it the end? Sem Nephrol, 10: 228–241, 1990.Google Scholar
  23. 23.
    Bank N: Mechanisms of diabetic hyperfiltration. Kidney Int, 40: 792–908, 1991.PubMedCrossRefGoogle Scholar
  24. 24.
    Mogensen CE, Andersen MJF: Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: Normalization by insulin treatment Diabetologia, 11: 221–224, 1975.PubMedCrossRefGoogle Scholar
  25. 25.
    Christiansen JS, Gammelgaard J, Tronier B, Svendsen PA, Parving H-H: Kidney function and size in diabetics before and during insulin treatment. Kidney Int, 21: 683–688, 1982.PubMedCrossRefGoogle Scholar
  26. 26.
    Christiansen JS, Frandsen M, Parving H-H: The effect of intravenous insulin infusion on kidney function in insulin-dependent diabetes mellitus. Diabetologia, 20: 199–204, 1981.PubMedGoogle Scholar
  27. 27.
    Wiseman MJ, Saunders AJ, Keen H, Viberti GC: Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. N Engl J Med, 312: 617–621, 1985.PubMedCrossRefGoogle Scholar
  28. 28.
    Mogensen CE, Steffes MW, Decken T, Christiansen JS: Functional and morphological renal manifestations in diabetes mellitus. Diabetologia, 21: 89–93, 1981.PubMedCrossRefGoogle Scholar
  29. 29.
    Wiseman M, Viberti G, Mackintosh D, Jarrett RJ, Keen H: Glycemia, arterial pressure and microalbuminuria in type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 26: 401–405, 1984.PubMedCrossRefGoogle Scholar
  30. 30.
    Jones SL, Wiseman MJ, Viberti GC: Glomerular hyperfiltration as a risk factor for diabetic nephropathy: Five year report of a prospective study. Diabetologia, 34: 59–60, 1991 (Letter).PubMedCrossRefGoogle Scholar
  31. 31.
    Azevedo MJ, Gross JL: Follow up of glomerular hyperfiltration in normoalbuminuric type 1 (insulin-dependent) diabetic patients. Diabetologia, 34:611, 1991 (Letter).PubMedCrossRefGoogle Scholar
  32. 32.
    Mogensen CE: Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy. Scand J Clin Lab Invest, 46: 201–206, 1986.PubMedCrossRefGoogle Scholar
  33. 33.
    Mogensen CE, Christensen CK Christiansesn JS, Boye N, Pedersen MM, Schmitz A: Early hyperfiltration and late, renal damage in insulin-dependent diabetes. Ped Adolesc Endocrinol, 17: 197–205, 1988.Google Scholar
  34. 34.
    Messent J, Jones S, Wiseman M, Viberti GC: Glomerular hyperfiltration and albuminuria A 8 year prospective study. Diabetologia (Suppl 2), 34: AI, 1991 (Abstract).Google Scholar
  35. 35.
    Lafferty HM, Brenner BM: Are glomerular hypertension and “hypertrophy” independent risk factors for progression of renal disease? Sem Nephrol, 3: 294–304, 1990.Google Scholar
  36. 36.
    Viberti GC, Pickup JC, Jarrett RJ, Keen H: Effect of control of blood glucose on urinary excretion of albumin and b2 microglobulin in insulin-dependent diabetics. N Engl J Med, 300: 638–641, 1979.PubMedCrossRefGoogle Scholar
  37. 37.
    Østerby R, Gundersen HJG: Glomerular size and structure in diabetes mellitus: 1. Early abnormalities. Diabetologia, 11: 225–229, 1975.PubMedCrossRefGoogle Scholar
  38. 38.
    Østerby R: Early phases in the development of diabetic glomerulopathy: Quantitative electron microscopic study. Acta Med Scand, S574 (Suppl): 3–82, 1974.Google Scholar
  39. 39.
    Østerby R: Basement membrane morphology in diabetes mellitus. In: “Diabetes Mellitus: theory and practice” (Eds M Ellenberg, H Rigkin), Medical Examination Publishing, New York, 1983, pp 323–341.Google Scholar
  40. 40.
    Østerby R: A quantitative electron microscopic study of mesangial regions in glomeruli from patients with short term juvenile diabetes mellitus. Lab Invest, 29: 99–110, 1973.PubMedGoogle Scholar
  41. 41.
    Vittinghus E, Mogensen CE: Albumin excretion and renal hemodynamic response to physical exercise in normal and diabetic man. Scand J Clin Lab Invest, 41: 627–632, 1981.PubMedCrossRefGoogle Scholar
  42. 42.
    Galling W, Knight C, Mullee MA, Hill RD: Microalbuminuria in diabetes: a population study of the prevalence and assessment of three screening tests. Diabetic Med, 5: 343–347, 1988.CrossRefGoogle Scholar
  43. 43.
    Rowe DJF, Bagga H, Betts PB: Normal variations in rate of albumin excretion and albumin to creatinine ratios in overnight and daytime urine collections in non-diabetic children. Br Med J, 291: 693–694, 1985.CrossRefGoogle Scholar
  44. 44.
    Chachati A, von Frenckell R, Foidart-Willems J, Godon JP, Lefèbvre PJ. Variability of albumin excretion in insulin-dependent diabetics, Diabetic Med, 4: 437–440, 1987.CrossRefGoogle Scholar
  45. 45.
    Cohen DL, Close CF, Viberti GC: The variability of overnight urinary albumin excretion in insulin-dependent diabetic and normal subjects. Diabetic Med, 4: 437–440, 1987.PubMedCrossRefGoogle Scholar
  46. 46.
    Parving H-H, Hommel E, Mathiesen E, Skøtt P, Edsberg B, Bahnsen M, Lauritzen M, Hougaard P, Lauritzen E: Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin-dependent diabetes. Br Med J, 296: 156–160, 1988.CrossRefGoogle Scholar
  47. 47.
    Viberti G, Keen H: The patterns of proteinuria in diabetes mellitus: relevance to pathogenesis and prevention of diabetic nephropathy. Diabetes, 33: 686–692, 1984.PubMedGoogle Scholar
  48. 48.
    Mogensen CE: Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int, 31: 673–689, 1987.PubMedCrossRefGoogle Scholar
  49. 49.
    Parving H, Øxenbøll B, Svendsen PA, Christiansen JS, Andersen AR: Early detection of patients at risk of developing diabetic nephropathy: a longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenhagen), 100: 550–555, 1982.Google Scholar
  50. 50.
    Mathiesen ER, Øxenbøll B, Johansen K, Svendsen PA, Deckert T. Incipient nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia, 26:406–410, 1984.PubMedCrossRefGoogle Scholar
  51. 51.
    Viberti GC, Hill RD, Jarrett RJ, Argyropoulous A, Mahmud U, Keen H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet, I: 1430–1432, 1982.CrossRefGoogle Scholar
  52. 52.
    Borch-Johnsen K: Incidence of nephropathy in insulin-dependent diabetes as related to mortality. In: “The kidney and hypertension in diabetes mellitus” (Ed CE Mogensen), Topics in Renal Medicine (Series Ed VE Andreucci), Martinus Nijhoff, Boston, 1988, pp 33–40.Google Scholar
  53. 53.
    Nørgaard K, Feldt-Rasmussen B, Borch-Johnsen K, Saelan H, Decken T: Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 33:407–410, 1990.PubMedCrossRefGoogle Scholar
  54. 54.
    Chavers BM, Bilous RW, Ellis EN, Steffes MW, Mauer SM: Glomerular lesions and urinary albumin excretion in type 1 diabetes without overt proteinuria N Engl J Med, 320: 966–970, 1989.PubMedCrossRefGoogle Scholar
  55. 55.
    Mogensen CE: Long term anti-hypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J, 285: 685–688, 1982.CrossRefGoogle Scholar
  56. 56.
    Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest, 74: 1143–1155, 1984.PubMedCrossRefGoogle Scholar
  57. 57.
    Steffes MW, Østerby R, Chavers B, Mauer SM: Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes, 38: 1077–1081, 1989.PubMedCrossRefGoogle Scholar
  58. 58.
    Gellman DD, Pirani CL, Soothill JF, Muehrcke RC, Maduros W, Kark RM: Structure and function in diabetic nephropathy. The importance of diffuse glomerulosclerosis. Diabetes, 8: 251–256, 1959.PubMedGoogle Scholar
  59. 59.
    Harris MI, Hadden WC, Knowles WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the United States population aged 20–74 years. Diabetes, 36: 523–534, 1987.PubMedCrossRefGoogle Scholar
  60. 60.
    Marks HH: Longevity and mortality of diabetics. Am J Public Health, 55: 416–422, 1965.CrossRefGoogle Scholar
  61. 61.
    Herman WH, Teutsch SM: Kidney disease associated with diabetes. Diabetes in America. Washington DC, US Govt Printing Office, pp 1–31, 1985 (NIH publication no. 85-1468).Google Scholar
  62. 62.
    Damsgaard EM, Mogensen CE: Microalbuminuria in elderly hyperglycemic patients and controls. Diabetic Med, 3: 430–435, 1986.PubMedCrossRefGoogle Scholar
  63. 63.
    Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT: The kidney in maturity onset diabetes: a clinical study of 510 patients. Kidney Int, 21: 730–738, 1982.PubMedCrossRefGoogle Scholar
  64. 64.
    Hasslacher CH, Ritz E, Wahl P: Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant, 4: 859–863, 1989.PubMedGoogle Scholar
  65. 65.
    Kunzelman CL, Knowles WC, Pettit DJ, Bennett PH: Incidence of proteinuria in type 2 diabetes in the Pima Indians. Kidney Int, 35: 681–687, 1989.PubMedCrossRefGoogle Scholar
  66. 66.
    Knowles WC, Bennett PH, Hamman RF, Miller M: Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota: Am J Epidemiol, 108: 497–505, 1978.Google Scholar
  67. 67.
    Nelson RG, Kunzelman CL, Pettit DJ, Saad MF, Bennett PH, Knowles WC: Albuminuria in type 2 (non-insulin dependent) diabetes mellitus and impaired glucose tolerance in Pima Indians. Diabetologia 32: 870–876, 1989.PubMedCrossRefGoogle Scholar
  68. 68.
    Nelson RG, Newman JM, Knowles WC, Sievers ML, Kunzelman CL, Pettit DJ, Moffet CD, Teutsch SM, Bennett PH: Incidence of end-stage renal disease in type 2 (non-insulin dependent) diabetes mellitus in Pima Indians. Diabetologia 31: 730–736, 1988.PubMedCrossRefGoogle Scholar
  69. 69.
    Ritz E, Nowack D, Fliser D, Koch M, Tschope W: Type II diabetes mellitus: Is the renal risk adequately appreciated? Nephrol Dial Transplant, 6: 679–682, 1991.PubMedGoogle Scholar
  70. 70.
    Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM: Disparities in incidence of diabetic end stage renal disease according to race and type of diabetes. N Engl J Med, 321: 1074–1079, 1989.PubMedCrossRefGoogle Scholar
  71. 71.
    Pugh JA, Stern MP, Haffner SM, Eifler CW, Zapata M: Excess incidence of end stage renal disease in Mexican Americans. Am J Epidemiol, 127: 135–144, 1988.PubMedGoogle Scholar
  72. 72.
    Nolph KD, Lundblad AS, Novak JW: Current concepts: Continuous ambulatory peritoneal dialysis. N Engl J Med, 318: 1595–1600, 1988.PubMedCrossRefGoogle Scholar
  73. 73.
    Friedman EA: Diabetic nephropathy. Strategies in prevention and management. Kidney Int, 21: 780–791, 1982.Google Scholar
  74. 74.
    Mogensen CE: Comparative renal pathophysiology relevant to IDDM and NIDDM patients. Diab Metab Rev, 4: 453–483, 1988.CrossRefGoogle Scholar
  75. 75.
    Friedman EA: No supranormal GFR in type II diabetes. Kidney Int, 31: 179, 1988 (Abstract).Google Scholar
  76. 76.
    Schmitz A, Hvid-Hansen H, Christensen T: Kidney function in newly diagnosed type 2 (non-insulin dependent) diabetes before and after treatment Diabetologia, 32: 434–439, 1989.PubMedCrossRefGoogle Scholar
  77. 77.
    Schmitz AH, Christensen T, Taagehoej, Jenson F: Glomerular filtration rate and kidney volume in normoalbuminuric non-insulin dependent diabetes: lack of glomerular hyperfíltration and renal hypertrophy in uncomplicated NIDDM. Scand J Clin Lab Invest, 49: 103–108, 1989.PubMedCrossRefGoogle Scholar
  78. 78.
    Schmitz A, Christensen T, Møller A, Mogensen CE: Kidney function and cardiovascular risk factors in non-insulin dependent diabetics (NIDDM) with microalbuminuria. J Int Med, 228: 347–352, 1990.CrossRefGoogle Scholar
  79. 79.
    Myers BD, Nelson RG, Williams GW, Bennett PH, Hardy SA, Berg RL, Loon NL, Knowler WC, Mitch WE: Glomerular function in Pima Indians with non-insulin dependent diabetes mellitus of recent onset. J Clin Invest, 88: 524–530, 1991.PubMedCrossRefGoogle Scholar
  80. 80.
    Lebovitz HE, Palmisano J: Cross-sectional analysis of renal function in black Americans with non-insulin dependent diabetes mellitus. Diabetes Care, 13(Suppl 4): 1186–1190, 1990.PubMedCrossRefGoogle Scholar
  81. 81.
    Palmisano JJ, Lebovitz HE: Renal function in black Americans with type II diabetes. J Diabetic Complications, 3: 40–44, 1989.CrossRefGoogle Scholar
  82. 82.
    Palmisano J, Sachmechi I: Renal function in type 2 diabetes. Diabetes, 36(Suppl 2): 206A, 1987 (Abstract).Google Scholar
  83. 83.
    Bérionade V: Creatinine clearance in non-insulin dependent diabetes mellitus. Kidney Int, 31: 179, 1986 (Abstract).Google Scholar
  84. 84.
    Bruton BL, Perusek MC, Lancaster JL, Kopp DT, Tuttle KR: Effects of glycemia on basal and amino-acid stimulated (AA-S) renal hemodynamics and kidney size in non-insulin dependent diabetes (NIDD). JASN, 1: 623, 1990 (Abstract).Google Scholar
  85. 85.
    Nowack R, Raum E, Blum W, Ritz E: Renal hemodynamics in recent onset type II diabetes. Am J Kid Dis (in press).Google Scholar
  86. 86.
    Davies DF, Shock NW: Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest, 29: 496–502, 1950.PubMedCrossRefGoogle Scholar
  87. 87.
    Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW: The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol, 31: 155–163, 1976.PubMedGoogle Scholar
  88. 88.
    Lindeman RD, Tobin JD, Shock NW: Longitudinal studies on the rate of decline in renal function with age. J Am Geriat Soc, 33: 278–285, 1985.PubMedGoogle Scholar
  89. 89.
    Takazakura E, Wasabu N, Handa A, Takada A, Shinoda A, Takeuchi J: Intrarenal vascular changes with age and disease. Kidney Int, 2: 224–230, 1972.PubMedCrossRefGoogle Scholar
  90. 90.
    Uusitupa M, Siitonen O, Penttila I, Aro A, Pyörälä K: Proteinuria in newly diagnosed type II diabetic patients. Diabetes Care, 10: 191–194, 1987.PubMedCrossRefGoogle Scholar
  91. 91.
    Gall MA, Rossing p, Skøtt P, Damsbo P, Vaag A, Bech K, Dejgaard A, Lauritzen M, Lauritzen E, Hougaard P, Beck-Nielsen H, Parving H-H: Prevalence of micro-and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin dependent) diabetic patients. Diabetologia, 34: 655–661, 1991.PubMedCrossRefGoogle Scholar
  92. 92.
    Parving H-H, Gall M-A, Skøtt P, Jørgensen HE, Jørgensen F, Larsen S: Prevalence and causes of albuminuria in non-insulin dependent diabetic (NIDDM) patients Kidney Int, 37: 243, 1990 (Abstract).Google Scholar
  93. 93.
    Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med, 310: 356–360, 1984.PubMedCrossRefGoogle Scholar
  94. 94.
    Mogensen CE: A complete screening of urinary albumin concentration in an unselected diabetic outpatient clinic population (1082 patients). Diabetic Nephropathy, 2: 11–18, 1983.Google Scholar
  95. 95.
    Jerums G, Cooper ME, Seeman E, Murray RML, McNeil J: Spectrum of proteinuria in type I and type II diabetes. Diabetes Care, 10: 419–427, 1987.PubMedCrossRefGoogle Scholar
  96. 96.
    Freidman R, Gross JL: Evolution of glomerular filtration rate in proteinuric NIDDM patients. Diabetes Care, 14: 355–359, 1991.CrossRefGoogle Scholar
  97. 97.
    Stein ACR: Estudio comparativo e evolutivo de pacientes diabéticos com diferentes graus de proteinuria. In: “Curso de Pos-Gradua-çao em Medicina: Nefrologia”. Universidade Federal de Rio Grande do Sul, Porto Alegre, Brasil, 1984, pp 85–90.Google Scholar
  98. 98.
    Yudkin JS, Forrest FD, Jackson CA: Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Lancet, I: 530–533, 1988.CrossRefGoogle Scholar
  99. 99.
    Schmitz A, Vaeth M: Microalbuminuria-a major risk factor in non-insulin dependent diabetes. A 10 year follow-up study of 503 patients. Diabetic Med, 5: 126–134, 1988.PubMedCrossRefGoogle Scholar
  100. 100.
    Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ: Microalbuminuria predicts mortality in non-insulin dependent diabetes. Diabetic Med, 1:17–19, 1984.PubMedCrossRefGoogle Scholar
  101. 101.
    Douglas JG: Hypertension and diabetes in blacks. Diabetes Care, 13(Suppl 4): 1191–1195, 1990.PubMedCrossRefGoogle Scholar
  102. 102.
    Reubi FC, Franz KA, Horber F: Hypertension as related to renal function in diabetes mellitus. Hypertension, 7(Suppl II): 21–28, 1985.Google Scholar
  103. 103.
    Jerums G, Cooper ME, Seeman E, Murray RM, McNeil JJ: Comparison of early renal dysfunction in type I and type II diabetes: differing associations with blood pressure and glycemic control. Diab Res Clin Prac, 4: 133–141, 1988.CrossRefGoogle Scholar
  104. 104.
    Jarrett RJ: Hypertension in diabetic patients and differences between insulin-dependent diabetes mellitus and non-insulin dependent diabetes mellitus. Am J Kid Dis, 13: 14–16, 1989.PubMedGoogle Scholar
  105. 105.
    Jarrett RJ: Hypertension in glucose intolerance and diabetes. J Int Med, 229 (Suppl 2): 85–88, 1991.Google Scholar
  106. 106.
    Standl E, Steigler H, Roth R, Shultz K, Lemacher K: On the impact of hypertension on the prognosis of NIDDM. Results of the Schwabing-GP program. Diab Metabol, 15: 352–358, 1989.Google Scholar
  107. 107.
    Panzram G: Mortality and survival in type 2 (non-insulin dependent) diabetes mellitus. Diabetologia, 30: 123–131, 1987.PubMedCrossRefGoogle Scholar
  108. 108.
    Ritz E, Hasslacher C, Beutel G: Hypertension and diabetic nephropathy. J Nephrol, 1: 11–15, 1991.Google Scholar
  109. 109.
    DeFronzo RJ, Ferranini E: Insulin resistance: A multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care, 14: 173–194, 1991.PubMedCrossRefGoogle Scholar
  110. 110.
    Viberti GC, Walker JD: Diabetic nephropathy: Etiology and prevention. Diab/Metab Rev, 4:147–162, 1988.CrossRefGoogle Scholar
  111. 111.
    Weidmann P, Beretta-Piccoli C, Trost BN: Pressure factors and responsiveness in hypertension accompanying diabetes mellitus. Hypertension, 7(Suppl 2): 33–42, 1985.Google Scholar
  112. 112.
    Cohen D, Dodds R, Viberti GC: Effect of protein restriction in insulin-dependent diabetics at risk of nephropathy. Br Med J, 294: 795–798, 1987.CrossRefGoogle Scholar
  113. 113.
    Christensen CK, Mogensen CE: The course of incipient diabetic nephropathy: studies of albumin excretion and blood pressure. Diabetic Med, 2: 97–102, 1985.PubMedCrossRefGoogle Scholar
  114. 114.
    Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR: A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia, 20: 457–461, 1981.PubMedCrossRefGoogle Scholar
  115. 115.
    Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic nephropathy. Proc Nat Acad Sci USA, 82: 5963–5967, 1985.PubMedCrossRefGoogle Scholar
  116. 116.
    Hostetter TH, Troy JL, Brenner BM: Glomerular hemodynamics in experimental diabetes. Kidney Int, 19: 410–415, 1981.PubMedCrossRefGoogle Scholar
  117. 117.
    Hostetter TH: Pathogenesis of diabetic glomerulopathy: Hemodynamic considerations. Sem Nephrol, 10: 219–227, 1990.Google Scholar
  118. 118.
    Bérionade VC, Lefèbvre R, Falardeau P: Unilateral nodular diabetic glomerulosclerosis: Recurrence of an experiment of nature. Am J Nephrol, 7: 55–59, 1987.CrossRefGoogle Scholar
  119. 119.
    Working Group on Hypertension in Diabetes. Statement on hypertension in diabetes mellitus. Final report Arch Int Med, 147: 830–842, 1987.Google Scholar
  120. 120.
    Mogensen CE: Renal function changes in diabetes. Diabetes, 25: 872–879, 1976.PubMedGoogle Scholar
  121. 121.
    Parving H-H, Andersen AR, Smidt UM, Svendsen PAA: Early aggressive anti-hypertensive therapy reduces rate of decline in kidney function in diabetic nephropathy. Lancet, II: 1175–1179, 1983.CrossRefGoogle Scholar
  122. 122.
    Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J, 294: 1443–1447, 1987.CrossRefGoogle Scholar
  123. 123.
    Parving H-H, Andersen AR, Hommel E, Smidt U: Effects of long term antihypertensive treatment on kidney function in diabetic nephropathy. Hypertension, 7(Suppl II): 114–117, 1985.Google Scholar
  124. 124.
    Christensen CK, Mogensen CE: Acute and long term effect of antihypertensive treatment on exercise-induced albuminuria in incipient diabetic nephropathy. Scand J Clin Lab Invest, 46: 553–559, 1986.PubMedCrossRefGoogle Scholar
  125. 125.
    Mathiesen ER, Borch-Johnsen K, Jensen DV, Deckert T: Improved survival in patients with diabetic nephropathy. Diabetologia, 32: 884–886, 1989.PubMedCrossRefGoogle Scholar
  126. 126.
    Krolewski AS, Canessa M, Warren JH, Laffel LMB, Christlieb AR, Knowles WC, Rand LI: Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med, 318: 140–145, 1988.PubMedCrossRefGoogle Scholar
  127. 127.
    Mangili R, Bending JJ, Scott G, Li LK, Gupta A, Viberti G: Increased sodium-lithium countertransport activity on red cells of patients with insulin-dependent diabetes and nephropathy. N Engl J Med, 318: 146–150, 1988.PubMedCrossRefGoogle Scholar
  128. 128.
    Viberti G, Keen H, Wiseman MJ: Raised arterial pressure in parents of proteinuric insulin-dependent diabetics. Br Med J, 295: 515–519, 1987.CrossRefGoogle Scholar
  129. 129.
    Ibsen KK, Jensen HA, Wieth JC, Funder J: Essential hypertension: Sodium-lithium countertransport in erythrocytes from patients and from children having one hypertensive parent Hypertension, 4: 703–709, 1982.PubMedGoogle Scholar
  130. 130.
    Carr S, Mbanya JC, Thomas T, Keavey P, Taylor R, Alberti KGMM, Wilkinson R. Increase in glomerular filtration rate in patients with insulin-dependent diabetes and elevated erythrocyte Na-Li countertransport. N Engl J Med, 322: 500–505, 1990.PubMedCrossRefGoogle Scholar
  131. 131.
    Jensen JJ, Mathiesen ER, Norgaard K, Hommel E, Borch-Johnsen K, Funder J, Brahm J, Parving H-H, Deckert T: Increased blood pressure and sodium-lithium countertransport activity are not inherited in diabetic nephropathy. Diabetologia, 33: 619–624, 1990.PubMedCrossRefGoogle Scholar
  132. 132.
    Rutherford PA, Thomas TH, Wilkinson R: The mechanism of raised sodium-lithium countertransport in Type I diabetes mellitus is different from that in essential hypertension. Diabetic Med, 7(Suppl 2): 1A, 1990 (Abstract).Google Scholar
  133. 133.
    Baba T, Tomiyama T, Murabayashi S, Takebe K: Renal effects of nicardipine, a calcium antagonist, in hypertensive type 2 (non-insulin dependent) diabetic patients with and without nephropathy. Eur J Clin Pharmacol, 38: 425–429, 1990.PubMedCrossRefGoogle Scholar
  134. 134.
    D’Angelo A, Giannini S, Benetollo P, Castrignano R, Lodetti MG, Malvasi L, Pati T, Crepaldi G: Efficacy of Captopril in hypertensive diabetic patients. Am J Med, 84(Suppl 3A): 155–158, 1988.PubMedCrossRefGoogle Scholar
  135. 135.
    Romero I, Salinas I, Teixidó J, Lucas A, Felip A, Sanmarti A: Long term follow up of the effect Captopril on severe proteinuria in hypertensive diabetic patients. J Human Hypertension, 4: 671–675, 1990.Google Scholar
  136. 136.
    Valvo F, Bedogna V, Casagrande P, Antiga L, Zamboui M, Bonmartini F, Oldrizzi L, Rugin C, Maschio G: Captopril in patients with type 2 diabetes and renal insufficiency: systemic and renal hemodynamic alterations. Am J Med, 85: 344–348, 1988.PubMedCrossRefGoogle Scholar
  137. 137.
    Cheng KP, Ma JTC, Yeh GR, Chan MK: Comparison of Captopril and enalapril in the treatment of hypertension in patients with non-insulin dependent diabetes mellitus and nephropathy. Int Urol Nephrol, 22: 295–303, 1990.PubMedCrossRefGoogle Scholar
  138. 138.
    Hasslacher CH, Borgholtz G, Ritz E, Wahl P: Impact of hypertension on prognosis in insulin-dependent diabetes mellitus. Diab Métab (Paris), 15: 338–342, 1989.Google Scholar
  139. 139.
    Zatz R, Dunn BR, Meyer TW, Andersen S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest, 77: 1925–1930, 1986.PubMedCrossRefGoogle Scholar
  140. 140.
    Fujihara CK, Padilha RM, Zatz R: Glomerular abnormalities in long term experimental diabetes. Role of hemodynamic and non-hemodynamic factors and effect of antihypertensive therapy. Diabetes, 41: 286–293, 1992.PubMedCrossRefGoogle Scholar
  141. 141.
    Bank N, Klose R, Aynedjian HS, Nguyen D, Sablay LB: Evidence against increased glomerular pressure initiating diabetic nephropathy. Kidney Int, 31: 898–905, 1987.PubMedCrossRefGoogle Scholar
  142. 142.
    Rabkin R, Petersen J, Kitaji J, Marck B, Murphy W, Muirhead EE: Effect of antihypertensive therapy on the kidney in spontaneously hypertensive rats with diabetes. Kidney Int, 25: 205, 1984 (Abstract).Google Scholar
  143. 143.
    Fujihara CK, Padilha RM, Santos MM, Zatz K: Role of glomerular hypertension, glomerular hypertrophy and lipid deposition in the genesis of glomerulosclerosis of experimental diabetes. Kidney Int, 37: 506, 1990 (Abstract).Google Scholar
  144. 144.
    Andersen S, Rennke HG, Garcia DL, Brenner BM: Short-and long-term effects of antihypertensive therapy in the diabetic rat. Kidney Int, 36: 526–536, 1989.CrossRefGoogle Scholar
  145. 145.
    Fogo A, Yoshida Y, Ichikawa I: Angiotensin converting enzyme inhibition (CEI) suppresses accelerated growth of glomerular cells in vivo and vitro. Kidney Int, 33, 296, 1986 (Abstract).Google Scholar
  146. 146.
    Galler M, Backenroth R, Folkert VW, Schlondorff D: Effect of converting enzyme inhibitors on prostaglandin synthesis by isolated glomerular and aortic strips from rats. J Pharmacol Exp Ther, 220: 23–28, 1982.PubMedGoogle Scholar
  147. 147.
    Homma T, Ichikawa I, Hoover RL: Prostaglandins of mesangium origin inhibit mesangial cell proliferation and matrix synthesis. Kidney Int, 33: 268, 1988 (Abstract).Google Scholar
  148. 148.
    Morelli E, Loon N, Meyer T, Peters W, Myers BD: Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes, 39: 76–82, 1990.PubMedCrossRefGoogle Scholar
  149. 149.
    Pollare T, Lithell H Berne C: A comparison of the effect of hydrochlorothiazide and Captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med, 321: 868–873, 1989.PubMedCrossRefGoogle Scholar
  150. 150.
    Rett K, Jauch KW, Wicklmayr M, Dietze G, Fink E, Mehnert H: Angiotensin converting enzyme inhibitors in diabetes: Experimental and human experience. Postgrad Med J, 62(Suppl 2): 59–64, 1986.PubMedGoogle Scholar
  151. 151.
    Hommel E, Parving H-H, Mathiesen E, Edsberg B, Damkjæ Nielsen M, Giese J: Effect of Captopril on kidney function in insulin-dependent diabetics with nephropathy, Br Med J, 293: 467–470, 1986.CrossRefGoogle Scholar
  152. 152.
    Marre M, Leblanc H, Suarez I, Thanh-Tam G, Menard J, Possa P: Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J, 294: 1448–1452, 1987.CrossRefGoogle Scholar
  153. 153.
    Parving H-H, Hommel E, Smidt UM: Protection of kidney function and decrease in albuminuria by Captopril in insulin dependent diabetics with nephropathy. Br Med J, 297: 1086–1091, 1988.CrossRefGoogle Scholar
  154. 154.
    Mimran A, Insua A, Ribstein J, Monnier L, Bringer J, Mirouze J: Contrasting effects of Captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. J Hypertension, 6: 919–923, 1988.CrossRefGoogle Scholar
  155. 155.
    Parving H-H, Hommel E, Nielsen MD, Giese J: Effect of Captopril on blood pressure and kidney function in normotensive insulin-dependent diabetics with nephropathy. Br Med J, 299: 533–536, 1989.CrossRefGoogle Scholar
  156. 156.
    Weigmann TB, Herron KG, Chonko AM, MacDougall ML, Moore WV: Effect of angiotensin-converting enzyme inhibition on renal function and albuminuria in normotensive type 1 diabetic patients. Diabetes, 41: 62–67, 1992.CrossRefGoogle Scholar
  157. 157.
    Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y: Effect of Captopril on heavy proteinuria in azotemic diabetics. N Engl J Med, 313: 1617–1620, 1985.PubMedCrossRefGoogle Scholar
  158. 158.
    Bjorck S, Nyberg G, Mulec H, Goran G, Herletz H, Aureli M: Beneficial effect of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J, 293: 471–474, 1986.CrossRefGoogle Scholar
  159. 159.
    Holdaas H, Hartmann A, Lien MG, Nilsen L, Fauchai P, Jervell J, Berg KJ: Lisinopril, but not nifedipine, reduces urinary albumin excretion in diabetic nephropathy. Kidney Int, 37: 239, 1990 (Abstract).Google Scholar
  160. 160.
    Bjorck S, Mulec H, Johnsen SA, Nyberg G, Aurell M: Enalapril but not metoprolol reduces proteinuria in diabetic nephropathy. Kidney Int, 37: 236, 1990 (Abstract).Google Scholar
  161. 161.
    Henry RR, Wallace P, Olefsky JM: Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin dependent diabetes mellitus. Diabetes, 35: 990–998, 1986.PubMedCrossRefGoogle Scholar
  162. 162.
    Schneider SH, Vitug A, Ruderman SV: Atherosclerosis and physical activity. Diab/Metab Rev, 1: 513–553, 1986.CrossRefGoogle Scholar
  163. 163.
    Maschio G, Oldrizi L, Rugiu C: The effects of dietary protein restriction on the course of early chronic failure. In: “The progressive nature of renal disease”. Contemporary issues in Nephrology, vol 14 (Eds Mitch WE, Brenner BM, Stein JH), Churchill-Livingstone, New York, 1986, pp 203–210.Google Scholar
  164. 164.
    Bosch JP, Sacaggi A, Lauer A, Ronco C, Belledonne M, Glabman S: Renal functional reserve in humans. Am J Med, 75: 943–950, 1983.PubMedCrossRefGoogle Scholar
  165. 165.
    Kupin WL, Cortes P, Dumler S, Feldcamp CS, Kilates MC, Levin NW: Effect on renal function on change from high to moderate protein intake in type 1 diabetic patients. Diabetes, 36: 73–79, 1987.PubMedCrossRefGoogle Scholar
  166. 166.
    Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR: The changing natural history of nephropathy in type 1 diabetes. Am J Med, 78: 785–794, 1985.PubMedCrossRefGoogle Scholar
  167. 167.
    Tuttle KR, Bruton L, Perusek MC, Lancaster JL, Kopp DT, DeFronzo R: Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent in insulin-dependent diabetes mellitus. N Engl J Med, 324: 1626–1632, 1991.PubMedCrossRefGoogle Scholar
  168. 168.
    Wen S-F, Huang T-P, Moorthy AV: Effects of low-protein diet on experimental diabetic nephropathy in the rat J Lab Clin Med, 106: 589–597, 1985.PubMedGoogle Scholar
  169. 169.
    Rennke HG, Sandstrom D, Zatz R, Meyer TW, Cowan RS, Brenner BM. The role of dietary protein in the development of glomerular structural abnormalities in long term experimental diabetes mellitus. Kidney Int, 29: 289, 1986 (Abstract).Google Scholar
  170. 170.
    Bending JJ, Dodds RA, Keen H, Viberti GC: Renal response to restricted protein intake in diabetic nephropathy. Diabetes, 37: 1641–1646, 1988.PubMedCrossRefGoogle Scholar
  171. 171.
    Zeller KR, Jacobsen H: Reducing dietary protein intake to retard progression of diabetic nephropathy. Am J Kid Dis, 13: 17–19, 1989.PubMedGoogle Scholar
  172. 172.
    El Nahas AM, Coles GA: Dietary treatment of chronic renal failure: ten unanswered questions. Lancet, I: 597–600, 1986.CrossRefGoogle Scholar
  173. 173.
    Barsotti G, Morelli E, Gianonni A, Guiducci A, Lupetti S, Giovanetti S: Restricted phosphorus and nitrogen intake to slow the progression of chronic renal failure: A controlled trial. Kidney Int, 16 (Suppl): S278–S284, 1983.Google Scholar
  174. 174.
    Mitch WE, Walser M, Steinman TI, Hill S, Zeger S, Tungsanga K: The effects of a keto-amino acid supplement to a restricted diet on the progression of chronic renal failure. N Engl J Med, 311: 623–629, 1984.PubMedCrossRefGoogle Scholar
  175. 175.
    Rosman JB, ter Wee PM, Meijer S, Piers-Becht TPM, Sluiter WJ, Donker AJM: Prospective randomised trial of early dietary protein restriction in chronic renal failure. Lancet, II: 1291–1296, 1984.CrossRefGoogle Scholar
  176. 176.
    Azevedo MJ, Padilha LM, Gross JL: A short-term low-protein diet reduces glomerular filtration rate in insulin-dependent diabetes mellitus patients. Brazilian J Med Biol Res, 23: 647–654, 1990.Google Scholar
  177. 177.
    Rudberg S, Dalquist G, Aperia A, Persson B: Reduction of protein intake decreases glomerular filtration rate in young type 1 (insulin-dependent) diabetic patients mainly in hyperfiltering patients. Diabetologia, 31: 878–883, 1988.PubMedCrossRefGoogle Scholar
  178. 178.
    Pedersen MM, Mogensen CE, Jørgensen SF, Møller B, Lykhe G, Pederson O: Renal effects from limitation of high dietary protein in normoalbuminuric diabetic patients. Kidney Int, Suppl 27: S115–S121, 1989.Google Scholar
  179. 179.
    Zeller, Whittaker E, Sullivan L, Raskin P, Jacobsen HR: Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl Med, 324: 78–84, 1991.CrossRefGoogle Scholar
  180. 180.
    Evanoff G, Thompson C, Brown J, Weinman E: Prolonged dietary protein restriction in diabetic nephropathy. Arch Int Med, 149: 1129–1133, 1989.CrossRefGoogle Scholar
  181. 181.
    Walker JD, Bending JJ, Dodds RA, Mattock MB, Murrells TJ, Keen H, Viberti GC: Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet, II: 1411–1414, 1989.CrossRefGoogle Scholar
  182. 182.
    Viberti GC, Dodds RA, Bending JJ: Non-glycemic intervention in diabetic nephropathy: The role of dietary protein intake. In: “The kidney and hypertension in diabetes” (Ed CE Mogensen), Topics in Renal Medicine (Series Ed VE Andreucci), Martinus Nijhoff, Boston, 1988, pp 205–215.Google Scholar
  183. 183.
    Evanoff GV, Thompson CS, Brown J, Weinman EJ: The effect of dietary protein restriction on the progression of diabetic nephropathy: a 12 month follow-up. Arch Int Med, 147: 492–495, 1987.CrossRefGoogle Scholar
  184. 184.
    Wiseman MJ, Bognetti E, Dodds R, Keen H, Viberti GC: Changes in renal function in response to protein restricted diet in type 1 (insulin-dependent) diabetic subjects. Diabetologia, 30 154–159, 1987.PubMedCrossRefGoogle Scholar
  185. 185.
    Barsotti G, Ciardella F, Morelli E, Cupisti A, Mantovanelli A, Giovanetti S: Nutritional treatment of renal failure in type 1 diabetes. Clin Nephrol, 29: 280–287, 1988.PubMedGoogle Scholar
  186. 186.
    Anderson S: Low protein diets and diabetic nephropathy. Sem Nephrol, 3: 287–293, 1990.Google Scholar
  187. 187.
    Kaysen G, Gambertoglio J, Jiminez I, Jones H, Huthchinson FN: Effects of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int, 29: 572–577, 1986.PubMedCrossRefGoogle Scholar
  188. 188.
    El Nahas AM, Masters-Thomas A, Brady SA, Farrington K, Wilkinson V, Hilson AJW, Varghese Z, Moorhead JF: Selective effects of low protein diets in renal diseases. Br Med J, 289: 1337–1341, 1984.CrossRefGoogle Scholar
  189. 189.
    Shichiri M, Nishio Y, Ogura M, Marumo F: Effect of low-protein, very-low-phosphorus diet on diabetic renal insufficiency with proteinuria. Am J Kid Dis, 18: 26–32, 1991.PubMedGoogle Scholar
  190. 190.
    Wylie-Rosett J: Evaluation of protein in dietary management of diabetes mellitus. Diabetes Care, 11: 143–148, 1988.PubMedCrossRefGoogle Scholar
  191. 191.
    Fox CJ, Darby SC, Ireland JT, Sönksen PH: Blood glucose control and glomerular capillary basement membrane thickening in experimental diabetes. Br Med J, 2: 605–607, 1977.PubMedCrossRefGoogle Scholar
  192. 192.
    Mauer SF, Steffes MW, Sutherland D, Najarian J, Michael AF, Brown DM: Studies of the rate of regression of the glomerular lesions in diabetic rats treated with pancreatic islet transplantation. Diabetes, 24: 280–285, 1975.PubMedCrossRefGoogle Scholar
  193. 193.
    Weil R, Nozawara M, Koss M, Weber C, Reemtsma K, Mcintosh RM: Pancreatic transplantation in diabetic rats: renal function, morphology, ultrastructure and immunohistology. Surgery, 78: 142–148, 1975.PubMedGoogle Scholar
  194. 194.
    Mauer SM, Steffes MW, Brown DM: Animal models of diabetic nephropathy. Adv Nephrol, 8: 280–285, 1975.CrossRefGoogle Scholar
  195. 195.
    Skyler JS: Complications of diabetes mellitus: relationship to metabolic dysfunction. Diabetes Care, 2: 499–509, 1979.Google Scholar
  196. 196.
    Rosenstock J, Friberg T, Raskin P: Effect of glycemic control on microvascular complications in patients with type I diabetes mellitus. Am J Med, 81: 1012–1018, 1986.PubMedCrossRefGoogle Scholar
  197. 197.
    Hasslacher C, Ritz E: Effect of control of diabetes mellitus on progression of renal failure. Kidney Int, 32(Suppl 22): 53–56, 1987.Google Scholar
  198. 198.
    Mathiesen ER, Ronn B, Jensen T, Storm B, Deckert T: Microalbuminaria is prior to elevation of blood pressure in diabetic nephropathy. In: “First Workshop on Blood Pressure and Diabetic Nephropathy: Pathogenesis and treatment”. EDNSG, Pisa, 1989 (Abstract).Google Scholar
  199. 199.
    Mauer SM, Steffes MW, Brown DM: The kidney in diabetes. Am J Med, 70: 603–612, 1981.PubMedCrossRefGoogle Scholar
  200. 200.
    Nyberg G, Bhlomé G, Nordén G: Input of metabolic control on progression of clinical diabetic nephropathy. Diabetologia, 30: 82–86, 1987.PubMedGoogle Scholar
  201. 201.
    Abouna GM, Al-Adnani MS, Kremer GD, Kumar SA, Daddah SK, Kusma G: Reversal of diabetic nephropathy in human cadaveric kidneys after transplantation into non-diabetic recipients. Lancet, II: 1274–1276, 1983.CrossRefGoogle Scholar
  202. 202.
    Abouna G, Adnani MS, Kumar MS, Samhan SA: Fate of transplanted kidneys with diabetic nephropathy. Lancet, I: 622–624, 1986.CrossRefGoogle Scholar
  203. 203.
    Christensen CK, Christiansen JS, Schmitz A, Christensen T, Hermansen K, Mogensen CE: Effect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients. A 2 year controlled study. J Diab Compl, 1: 91–95, 1987.CrossRefGoogle Scholar
  204. 204.
    Beck-Nielsen H, Richelsen B, Mogensen CE, Olsen T, Ehlers N, Nielsen CB, Charles P: Effect of insulin pump treatment for one year on renal function and retinal morphology in patients with IDDM. Diabetes Care, 85: 585–589, 1984.Google Scholar
  205. 205.
    Mogensen CE: Prevention and treatment of renal disease in insulin-dependent diabetes mellitus. Sem Nephrol, 10: 260–273, 1990.Google Scholar
  206. 206.
    Drury PL, Watkins PJ, Viberti GC, Walker JD: Diabetic nephropathy. Br Med Bull, 45: 127–147, 1989.PubMedGoogle Scholar
  207. 207.
    Tamborlane WV, Puklin JE, Bergman M, Verdonck C, Rudolf MC, Felig P, Genel L, Sherwin R: Long term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy. Diabetes Care, 5: 58–64, 1982.PubMedGoogle Scholar
  208. 208.
    Viberti GC, Bilous RW, Mackintosh B, Bending JJ, Keen H: Long term correction of hyperglycemia and progression of renal failure in insulin dependent diabetes. Br Med J, 286: 598–602, 1983.CrossRefGoogle Scholar
  209. 209.
    Bending JJ, Viberti GC, Watkins PJ, Keen H: Intermittent clinical proteinuria and renal function in diabetes: Evolution and the effect of glycemic control. Br Med J, 292: 83–86, 1986.CrossRefGoogle Scholar
  210. 210.
    The Kroc Collaboration Study Group: Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. N Engl J Med, 311: 365–372, 1984.CrossRefGoogle Scholar
  211. 211.
    Feldt-Rasmussen B, Mathiesen E, Deckert T: Effect of two years of strict metabolic control on the progression of incipient nephropathy in insulin-dependent diabetes. Lancet, II: 1300–1304, 1986.CrossRefGoogle Scholar
  212. 212.
    Rosenstock J, Raskin P: The effect of glycemic control on urinary excretion rate (AER) in type I diabetes mellitus. Diabetes, 36: 425, 1987 (Abstract).Google Scholar
  213. 213.
    Dahl-Jorgensen K, Hanssen KF, Kierulf P, Bjøro T, Sandvik L, Aagenaes O: Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. Acta Endocrinol, 117: 19–25, 1988.PubMedGoogle Scholar
  214. 214.
    Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T: Effect of improved metabolic control on kidney function in type I (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 34: 164–170, 1991.PubMedCrossRefGoogle Scholar
  215. 215.
    Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T: Steno Study Group. 2 years experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes, 34(Suppl 3): 74–79, 1985.PubMedGoogle Scholar
  216. 216.
    Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U: Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Int Med, 230: 101–108, 1991.CrossRefGoogle Scholar
  217. 217.
    The DCCT Research Group: The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase. Diabetes, 35: 530–545, 1986.CrossRefGoogle Scholar
  218. 218.
    The DCCT Research Group: Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care, 11: 567–573, 1988.CrossRefGoogle Scholar
  219. 219.
    Ballard DJ, Humphrey LL, Melton LJ 3rd, Frohnert PP, Chu PC, O’Fallon WM, Palumbo PJ Epidemiology of persistent proteinuria in type II diabetes mellitus. Diabetes, 37: 405–412, 1988.PubMedCrossRefGoogle Scholar
  220. 220.
    Takazakura E, Nakamoto Y, Hayakawa H, Kawai H, Muramoto S, Yoshida K, Shimizu M, Shinoda A, Takeuchi J: Onset and progression of diabetic glomerulosclerosis: a prospective study based on serial renal biopsies. Diabetes, 24: 1–9, 1975.PubMedCrossRefGoogle Scholar
  221. 221.
    Canill GF Jr. Will euglycemia prevent vasculopathy? In: “The Diabetic Renal-Retinal Syndrome. Prevention and Management” (Eds EA Friedman, FA L’Esperance Jr), Grane and Stratton, New York, 1982, pp 529–535.Google Scholar
  222. 222.
    Vasquez B, Flock EV, Savage PJ, Nagulesparan EA, Bennion LJ, Baitd HR, Bennett PH: Sustained reduction of proteinuria in Type 2 (non-insulin dependent) diabetes following diet-induced reduction of hyperglycemia. Diabetologia, 26: 127–133, 1984.PubMedCrossRefGoogle Scholar
  223. 223.
    Beyer-Mears A, Ku L, Cohen MP: Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil. Diabetes, 33: 604–606, 1984.PubMedCrossRefGoogle Scholar
  224. 224.
    Cohen MP, Dasmahapatra A, Shapiro E: Reduced glomerular Na-K triphosphatase activity in acute streptozotocin diabetes and its prevention by sorbinil. Diabetes, 34: 1071–1075, 1985.PubMedCrossRefGoogle Scholar
  225. 225.
    Craven P, DeRubertis FR: Sorbinil suppresses glomerular prostaglandin production and reduces hyperfiltration in the streptozotocin-diabetic rat Clin Research, 36: 517a, 1988.Google Scholar
  226. 226.
    Goldfarb S, Simmons DA, Kerns EFO: Amelioration of glomerular hyperfiltration in acute experimental diabetes mellitus by dietary myo-inositol supplementation and aldose reductase inhibition> Trans Assoc Am Phys, 99: 67–72, 1986.PubMedGoogle Scholar
  227. 227.
    Mower P, Wildes B, Bank N: Sorbinil correction of diabetic hyperfiltration unassociated with changes in AII receptors. Kidney Int, 33: 380, 1988 (Abstract).Google Scholar
  228. 228.
    Tilton RG, Chang K, Pugliese G, Kilo C, Williamson JR: Inhibitors of aldose reductase block diabetes-induced increases in blood flow and glomerular filtration rate and markedly reduce 24 hour urinary albumin excretion in the rat. Diabetes, 36 (Suppl 1): 43, 1987 (Abstract).Google Scholar
  229. 229.
    Chang WP, Dimitriadis E, Allen T, Dunlop ME, Cooper M, Larkins RG: The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus. Diabetologia, 34: 225–231, 1991.PubMedCrossRefGoogle Scholar
  230. 230.
    Pedersen MM: Renal effects of an aldose reductase inhibitor (starli) during 6 months of treatment in type I (insulin-dependent diabetic patients. Diabetologia, 32: 516A, 1989 (Abstract).Google Scholar
  231. 231.
    Brownlee M: Glycosylation of proteins and microangiopathy. Hosp Pract, 27: 46–50, 1992.Google Scholar
  232. 232.
    Makita Z, Radoff F, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end-products in patients with diabetic nephropathy. N Engl J Med, 325: 836–842, 1991.PubMedCrossRefGoogle Scholar
  233. 233.
    Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue: Biochemical basis for a new therapeutic approach to the complications of diabetes. N Engl J Med, 318: 1315–1321, 1988.PubMedCrossRefGoogle Scholar
  234. 234.
    Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat Diabetes, 40: 1328–1332, 1991.PubMedCrossRefGoogle Scholar
  235. 235.
    Yamin MA, Brownlee M, Cerami A, Vlassara H: Nonenzymatic glycosylation of matrix and the pathogenesis of diabetic angiopathy. J Nephrol, 1: 23–26, 1991.Google Scholar
  236. 236.
    Edelstein BD, Brownlee M: Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia, 35: 96–97, 1992.PubMedCrossRefGoogle Scholar
  237. 237.
    Craven PA, Caines MA, DeRubertis FR: Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: Relationship to the hyperfiltration of early diabetes. Metabolism, 36: 95–103, 1987.PubMedCrossRefGoogle Scholar
  238. 238.
    Gambardello S, Andreani D, Cancelli A: Renal hemodynamics and urinary excretion of 6-keto-prostaglandin Fla and thromboxane b2 in newly diagnosed type I diabetic patients. Diabetes, 37: 1044–1048, 1988.CrossRefGoogle Scholar
  239. 239.
    Trevisan R, Fioretto P, Giorato C, Sacerdoti D, Borsato M, Mantero F, Crepaldi G, Tiengo A, Nosadini R: Determinants of glomerular hyperfiltration in type 1 (insulin-dependent) diabetes. Diabetologia, 34: A62, 1991 (Abstract).Google Scholar
  240. 240.
    Craven PA, DeRubertis FR: Role for local prostaglandin and thromboxane production in the regulation of glomerular filtration rate in the rat with streptozotocin-induced diabetes. J Lab Clin Med, 113: 674–681, 1989.PubMedGoogle Scholar
  241. 241.
    Jensen PK, Steven K, Blaehr H, Christiansen JS, Parving H-H: Effects of indomethacin on glomerular hemodynamics in experimental diabetes. Kidney Int, 29: 490–495, 1986.PubMedCrossRefGoogle Scholar
  242. 242.
    Tagiri Y, Inoguchi T, Umeda F, Nawata H: Reduction of urinary albumin excretion by thromboxane synthetase inhibitor, OKY-046, through modulating renal prostaglandins in patients with diabetic nephropathy. Diab Res Clin Pract, 10: 231–239, 1990.CrossRefGoogle Scholar
  243. 243.
    Christiansen JS, Feldt-Rasmussen B, Parving H-H: Short term inhibition of prostaglandin synthesis has no effect on the elevated glomerular filtration rate of early insulin-dependent diabetes. Diabetic Med, 2: 17–20, 1985.PubMedCrossRefGoogle Scholar
  244. 244.
    Esmatjes E, Fernandez MR, Halperin I, Camps J, Gaya J, Arroyo V, Rivera F, Figuerola D: Renal hemodynamic abnormalities in patients with short-term insulin dependent diabetes mellitus: role of renal prostaglandins. J Clin Endocrinol Metab, 60: 1231–1236, 1985.PubMedCrossRefGoogle Scholar
  245. 245.
    Hommel E, Mathiesen E, Arnold-Larsen S, Edsberg B, Olsen UB, Parving H-H: Effects of indomethacin on kidney function in type I (insulin-dependent) diabetic patients with nephropathy. Diabetologia, 30: 78–83, 1987.PubMedGoogle Scholar
  246. 246.
    Kasiske BL, O’Donnell MP, Schmitz PG, Keane WF: The role of lipid abnormalities in the pathogenesis of chronic, progressive renal disease. Adv Nephrol Necker Hosp, 20: 109–125, 1991.PubMedGoogle Scholar
  247. 247.
    Winocour PH, Durrington PN, Ishola M, Hillier VF, Anderson DC: The prevalence of hyperlipidemia and related clinical features in insulin-dependent diabetes mellitus. Q J Med, 70: 265–276, 1989.PubMedGoogle Scholar
  248. 248.
    Mulec H, Johnson S-A, Björck S: Relation between serum cholesterol and diabetic nephropathy. Lancet, 335: 1537–1538, 1990 (Letter).PubMedCrossRefGoogle Scholar
  249. 249.
    Kasiske BL, O’Donnell MP, Cleary MP, Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int, 33: 667–672, 1988.PubMedCrossRefGoogle Scholar
  250. 250.
    Kasiske BL, O’Donnell MP, Garvis WJ, Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res, 62: 367–374, 1988.PubMedGoogle Scholar
  251. 251.
    Kasiske BL, O’Donnell MP, Schmitz PG, Kim Y, Keane WF, Phillips F, Daniels F, Holden G: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int, 37: 880–891, 1990.PubMedCrossRefGoogle Scholar
  252. 252.
    Simpson LO: A hypothesis proposing increased blood viscosity as a cause of proteinuria and increased vascular permeability. Nephron, 31: 89–93, 1982.PubMedCrossRefGoogle Scholar
  253. 253.
    Simpson LO, Shand BI, Olds RJ: A reappraisal of the influence of blood rheology on glomerular filtration and its role in the pathogenesis of diabetic nephropathy. J Diabetic Compi, 1: 137–144, 1987.CrossRefGoogle Scholar
  254. 254.
    Solerte SB, Ferrari E: Diabetic retinal vascular complications, erythrocyte filtrability and pentoxifylline. Results of a 2 year follow-up study. Pharmatherapeutica, 4: 341–346 1985.PubMedGoogle Scholar
  255. 255.
    Solerte BF, Fioravante M, Bozzetti A, Schifino N, Patti AL, Fedele P, Viola C, Ferrari E: Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria. Results of a short-term randomised study. Acta Diabetol Lat, 23: 171–177, 1986.PubMedCrossRefGoogle Scholar
  256. 256.
    Brown CD, Friedman EA: Clinical and blood rheologic stability in erythropoietin-treated predialysis patients. Am J Nephrol, 10(Suppl 2): 29–33, 1990PubMedCrossRefGoogle Scholar
  257. 257.
    Mauer SM, Sutherland DER, Steffes MW, Leonard RJ, Najarían JS, Michael AF, Brown DM: Pancreatic islet transplantation. Effects on the glomerular lesions of experimental diabetes in the rat Diabetes, 23: 748–753, 1974.PubMedGoogle Scholar
  258. 258.
    Bilous RW, Mauer SM, Sutherland DER, Najarían JS, Goetz FC, Steffes MW: The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin dependent diabetes. N Engl J Med, 321: 80–85, 1989.PubMedCrossRefGoogle Scholar
  259. 259.
    Sawicki PT, Heinemann L, Muhlhauser I: Enalapril and metoprolol in diabetic nephropathy. Br Med J, 300: 1446–1448, 1990.CrossRefGoogle Scholar
  260. 260.
    Sawicki PT, Muhlhauser I, Baba T, Berger M: Do angiotensin converting enzyme inhibitors represent a progress in hypertensive care in diabetes mellitus? Diabetologia 33: 121–124, 1990.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1992

Authors and Affiliations

  • Anne Marie V. Miles
    • 1
  • Eli A. Friedman
    • 1
  1. 1.Renal Disease Division, Department of MedicineState University of New York, Health Science Center at BrooklynBrooklynUSA

Personalised recommendations